P300 Suppresses Leukemia Development in NHD13-driven Myelodysplastic Syndrome

Oncotarget - United States
doi 10.18632/oncotarget.23402
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Leukemia-Associated Inhibitory Activity in Acute Leukemia Developed From Myelodysplastic Syndrome.

Japanese Journal of Medicine
1987English

Biologic Characteristics of Acute Leukemia After Myelodysplastic Syndrome

Blood
BiochemistryImmunologyCell BiologyHematology
1993English

WT1 and GATA1 Expression in Myelodysplastic Syndrome and Acute Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
1999English

Therapy-Related Myelodysplastic Syndrome-Acute Myelogenous Leukemia in Patients Treated for Acute Promyelocytic Leukemia: An Emerging Problem

Blood
BiochemistryImmunologyCell BiologyHematology
2002English

Secondary Philadelphia Chromosome Acquired During Therapy of Acute Leukemia and Myelodysplastic Syndrome

Modern Pathology
Forensic MedicinePathology
2018English

Combinatorial Haplo-Deficient Tumor Suppression in 7q-Deficient Myelodysplastic Syndrome and Acute Myeloid Leukemia

Cancer Cell
Cancer ResearchOncologyCell Biology
2014English

Pattern Associated Leukemia Immunophenotypes and Measurable Disease Detection in Acute Myeloid Leukemia or Myelodysplastic Syndrome With Mutated NPM1

Cytometry Part B - Clinical Cytometry
Forensic MedicinePathologyHistologyCell Biology
2018English

Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia, and Acute Myeloid Leukemia Associated With Complete or Partial Monosomy 7

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
1999English

Sequential Allogeneic Stem Cell Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Biology of Blood and Marrow Transplantation
TransplantationHematology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy